Aged < 40 years | Placebo (n = 600) | Erenumab 70 mg (n = 517) | Erenumab 140 mg (n = 383) | Total (N = 1500) |
Age, mean (SD)a | 30.8 (5.8) | 30.2 (6.1) | 30.6 (5.7) | 30.5 (5.9) |
Female, n (%) | 495 (82.5) | 439 (84.9) | 316 (82.5) | 1250 (83.3) |
Race, n (%) | ||||
Asian | 161 (26.8) | 172 (33.3) | 116 (30.3) | 449 (29.9) |
White | 384 (64.0) | 295 (57.1) | 233 (60.8) | 912 (60.8) |
BMI (kg/m2), mean (SD) | 26.1 (6.0) | 26.1 (6.0) | 25.9 (6.0) | 26.0 (7.0) |
MMDs, mean (SD) | 10.4 (5.2) | 9.7 (4.7) | 10.2 (5.4) | 10.1 (5.1) |
MMDs, categories, n (%) | ||||
8–14 MMDs | 279 (46.5) | 238 (46.0) | 181 (47.3) | 698 (46.5) |
≥ 15 MMDs | 96 (16.0) | 67 (13.0) | 46 (12.0) | 209 (13.9) |
Medication overuse, n (%)b | ||||
Yes | 37 (6.2) | 29 (5.6) | 23 (6.0) | 89 (5.9) |
No | 77 (12.8) | 48 (9.3) | 42 (11.0) | 167 (11.1) |
PPTF, n (%) | ||||
0 | 363 (60.5) | 337 (65.2) | 211 (55.1) | 911 (60.7) |
1 | 102 (17.0) | 96 (18.6) | 70 (18.3) | 268 (17.9) |
2 | 48 (8.0) | 41 (7.9) | 46 (12.0) | 135 (9.0) |
≥ 3 | 87 (14.5) | 43 (8.3) | 56 (14.6) | 186 (12.4) |
Framingham cardiovascular risk factors | ||||
Cigarette use, n (%) | ||||
Current | 30 (5.0) | 36 (7.0) | 26 (6.8) | 92 (6.1) |
Former | 33 (5.5) | 28 (5.4) | 10 (2.6) | 71 (4.7) |
Never | 195 (32.5) | 177 (34.2) | 108 (28.2) | 480 (32.0) |
Unknown | 342 (57.0) | 276 (53.4) | 239 (62.4) | 857 (57.1) |
Diabetes, n (%) | 3 (0.5) | 4 (0.8) | 3 (0.8) | 10 (0.7) |
Hypertension, n (%) | 39 (6.5) | 22 (4.3) | 18 (4.7) | 79 (5.3) |
Total cholesterol (mmol/L), mean (SD) | 4.6 (1.0) | 4.6 (0.8) | 4.6 (1.0) | 4.6 (0.8) |
HDL cholesterol (mmol/L), mean (SD) | 1.4 (0.4) | 1.4 (0.4) | 1.4 (0.4) | 1.4 (0.4) |
Systolic BP (mmHg), mean (SD) | 116.9 (11.9) | 115.4 (11.4) | 115.7 (11.6) | 116.1 (12.0) |
Coronary artery disease, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Cerebrovascular or peripheral artery disease, n (%) | 1 (0.2) | 0 (0.0) | 2 (0.5) | 3 (0.2) |
Aged 40–49 years | Placebo (n = 426) | Erenumab 70 mg (n = 361) | Erenumab 140 mg (n = 278) | Total (N = 1065) |
Age, mean (SD) | 44.4 (2.8) | 44.4 (2.8) | 44.6 (2.8) | 44.4 (2.8) |
Female, n (%) | 361 (84.7) | 303 (83.9) | 237 (85.3) | 901 (84.6) |
Race, n (%) | ||||
Asian | 78 (18.3) | 82 (22.7) | 45 (16.2) | 205 (19.2) |
White | 317 (74.4) | 259 (71.7) | 224 (80.6) | 800 (75.1) |
BMI (kg/m2), mean (SD) | 26.6 (5.3) | 26.3 (5.3) | 26.1 (4.9) | 26.4 (5.2) |
MMDs, mean (SD) | 10.3 (4.7) | 9.7 (4.4) | 10.9 (4.8) | 10.2 (4.6) |
MMDs, categories, n (%) | ||||
8–14 MMDs | 224 (52.6) | 186 (51.5) | 141 (50.7) | 551 (51.7) |
≥ 15 MMDs | 63 (14.8) | 40 (11.1) | 52 (18.7) | 155 (14.6) |
Medication overuse, n (%)b | ||||
Yes | 42 (9.9) | 31 (8.6) | 27 (9.7) | 100 (9.4) |
No | 49 (11.5) | 33 (9.1) | 43 (15.5) | 125 (11.7) |
PPTF, n (%) | ||||
0 | 182 (42.7) | 200 (55.4) | 122 (43.9) | 504 (47.3) |
1 | 90 (21.1) | 67 (18.6) | 36 (12.9) | 193 (18.1) |
2 | 68 (16.0) | 47 (13.0) | 61 (21.9) | 176 (16.5) |
≥ 3 | 86 (20.2) | 47 (13.0) | 59 (21.2) | 192 (18.0) |
Framingham cardiovascular risk factors | ||||
Cigarette use, n (%) | 17 (4.0) | 20 (5.5) | 9 (3.2) | 46 (4.3) |
Current | 39 (9.2) | 32 (8.9) | 18 (6.5) | 89 (8.4) |
Former | 135 (31.7) | 145 (40.2) | 75 (27.0) | 355 (33.3) |
Never | 235 (55.2) | 164 (45.4) | 176 (63.3) | 575 (54.0) |
Unknown | 9 (2.1) | 8 (2.2) | 3 (1.1) | 20 (1.9) |
Diabetes, n (%) | 55 (12.9) | 41 (11.4) | 35 (12.6) | 131 (12.3) |
Hypertension, n (%) | 17 (4.0) | 20 (5.5) | 9 (3.2) | 46 (4.3) |
Total cholesterol (mmol/L), mean (SD) | 5.1 (0.9) | 5.0 (0.9) | 5.0 (0.9) | 5.0 (0.9) |
HDL cholesterol (mmol/L), mean (SD) | 1.5 (0.4) | 1.5 (0.4) | 1.5 (0.4) | 1.5 (0.4) |
Systolic BP (mmHg), mean (SD) | 120.0 (12.4) | 119.0 (13.0) | 119.6 (13.2) | 119.5 (12.8) |
Coronary artery disease, n (%) | 2 (0.5) | 1 (0.3) | 0 (0.0) | 3 (0.3) |
Cerebrovascular or peripheral artery disease, n (%) | 4 (0.9) | 1 (0.3) | 1 (0.4) | 6 (0.6) |
Aged 50–59 years | Placebo (n = 263) | Erenumab 70 mg (n = 216) | Erenumab 140 mg (n = 158) | Total (N = 637) |
Age, mean (SD) | 53.9 (2.8) | 53.9 (2.8) | 53.7 (2.8) | 53.8 (2.8) |
Female, n (%) | 220 (83.7) | 178 (82.4) | 133 (84.2) | 531 (83.4) |
Race, n (%) | ||||
Asian | 36 (13.7) | 23 (10.6) | 15 (9.5) | 74 (11.6) |
White | 208 (79.1) | 179 (82.9) | 128 (81.0) | 515 (80.8) |
BMI (kg/m2), mean (SD) | 25.8 (5.3) | 26.8 (5.3) | 25.7 (4.9) | 26.1 (5.2) |
MMDs, mean (SD) | 10.9 (5.6) | 10.2 (4.9) | 10.8 (5.1) | 10.6 (5.3) |
MMDs, categories, n (%) | ||||
8–14 MMDs | 117 (44.5) | 98 (45.4) | 67 (42.4) | 282 (44.3) |
≥ 15 MMDs | 51 (19.4) | 37 (17.1) | 39 (24.7) | 127 (19.9) |
Medication overuse, n (%)b | ||||
Yes | 31 (11.8) | 15 (6.9) | 25 (15.8) | 71 (11.1) |
No | 30 (11.4) | 28 (13.0) | 22 (13.9) | 80 (12.6) |
PPTF, n (%) | ||||
0 | 115 (43.7) | 101 (46.8) | 67 (42.4) | 283 (44.4) |
1 | 55 (20.9) | 54 (25.0) | 21 (13.3) | 130 (20.4) |
2 | 40 (15.2) | 25 (11.6) | 21 (13.3) | 86 (13.5) |
≥ 3 | 53 (20.2) | 36 (16.7) | 49 (31.0) | 138 (21.7) |
Framingham cardiovascular risk factors | ||||
Cigarette use, n (%) | ||||
Current | 14 (5.3) | 11 (5.1) | 6 (3.8) | 31 (4.9) |
Former | 28 (10.6) | 31 (14.4) | 20 (12.7) | 79 (12.4) |
Never | 81 (30.8) | 93 (43.1) | 35 (22.2) | 209 (32.8) |
Unknown | 140 (53.2) | 81 (37.5) | 97 (61.4) | 318 (49.9) |
Diabetes, n (%) | 13 (4.9) | 7 (3.2) | 3 (1.9) | 23 (3.6) |
Hypertension, n (%) | 56 (21.3) | 40 (18.5) | 25 (15.8) | 121 (19.0) |
Total cholesterol (mmol/L), mean (SD) | 5.5 (1.0) | 5.3 (1.0) | 5.4 (1.0) | 5.4 (1.0) |
HDL cholesterol (mmol/L), mean (SD) | 1.6 (0.5) | 1.6 (0.5) | 1.6 (0.5) | 1.6 (0.5) |
Systolic BP (mmHg), mean (SD) | 121.1 (14.8) | 122.2 (14.2) | 122.1 (13.8) | 121.7 (14.4) |
Coronary artery disease, n (%) | 0 (0.0) | 0 (0.0) | 2 (1.3) | 2 (0.3) |
Cerebrovascular or peripheral artery disease, n (%) | 0 (0.0) | 2 (0.9) | 1 (0.6) | 3 (0.5) |
Aged ≥ 60 years | Placebo (n = 70) | Erenumab 70 mg (n = 38) | Erenumab 140 mg (n = 35) | Total (N = 143) |
Age, mean (SD)a | 62.0 (1.6) | 62.1 (1.5) | 61.7 (1.6) | 61.9 (1.6) |
Female, n (%) | 55 (78.6) | 31 (81.6) | 27 (77.1) | 113 (79.0) |
Race, n (%) | ||||
Asian | 2 (2.9) | 3 (7.9) | 4 (11.4) | 9 (6.3) |
White | 65 (92.9) | 33 (86.8) | 31 (88.6) | 129 (90.2) |
BMI (kg/m2), mean (SD) | 26.3 (4.8) | 25.4 (5.6) | 26.1 (4.9) | 26.0 (5.0) |
MMDs, mean (SD) | 11.2 (5.5) | 10.7 (5.3) | 10.8 (3.7) | 11.0 (5.0) |
MMDs, categories, n (%) | ||||
8–14 MMDs | 36 (51.4) | 22 (57.9) | 22 (62.9) | 80 (55.9) |
≥ 15 MMDs | 14 (20.0) | 5 (13.2) | 5 (14.3) | 24 (16.8) |
Medication overuse, n (%)b | ||||
Yes | 7 (10.0) | 4 (10.5) | 3 (8.6) | 14 (9.8) |
No | 13 (18.6) | 3 (7.9) | 5 (14.3) | 21 (14.7) |
PPTF, n (%) | ||||
0 | 26 (37.1) | 17 (44.7) | 14 (40.0) | 57 (39.9) |
1 | 11 (15.7) | 7 (18.4) | 4 (11.4) | 22 (15.4) |
2 | 12 (17.1) | 7 (18.4) | 5 (14.3) | 24 (16.8) |
≥ 3 | 21 (30.0) | 7 (18.4) | 12 (34.3) | 40 (28.0) |
Framingham cardiovascular risk factors | ||||
Cigarette use, n (%) | ||||
Current | 3 (4.3) | 0 (0.0) | 0 (0.0) | 3 (2.1) |
Former | 15 (21.4) | 4 (10.5) | 3 (8.6) | 22 (15.4) |
Never | 20 (28.6) | 24 (63.2) | 9 (25.7) | 53 (37.1) |
Unknown | 32 (45.7) | 10 (26.3) | 23 (65.7) | 65 (45.5) |
Diabetes, n (%) | 1 (1.4) | 1 (2.6) | 1 (2.9) | 3 (2.1) |
Hypertension, n (%) | 19 (27.1) | 6 (15.8) | 9 (25.7) | 34 (23.8) |
Total cholesterol (mmol/L), mean (SD) | 5.3 (1.1) | 5.35 (0.8) | 5.6 (1.0) | 5.4 (1.0) |
HDL cholesterol (mmol/L), mean (SD) | 1.6 (0.4) | 1.8 (0.5) | 1.5 (0.4) | 1.6 (0.5) |
Systolic BP (mmHg), mean (SD) | 124.1 (12.9) | 120.6 (14.3) | 124.2 (15.4) | 123.2 (13.9) |
Coronary artery disease, n (%) | 1 (1.4) | 0 (0.0) | 0 (0.0) | 1 (0.7) |
Cerebrovascular or peripheral artery disease, n (%) | 3 (4.3) | 0 (0.0) | 2 (5.7) | 5 (3.5) |